Galmed Pharmaceuticals Ltd.
GLMD • Biotechnology
$3.88
▼ -0.04 (-1.02%)
Current price
EarningsSep 4, 11:12 AM UTC
New financial eventQ2 2026Negative
Galmed Pharmaceuticals Ltd. has reported Q2 2026 financial results
The latest report contains several weaker financial signals that deserve attention. Growth, profitability, cash generation, or financial strength may have deteriorated. The report may attract increased investor attention and price volatility.
Finzati signal
Caution warranted
Sep 4, 11:12 AM UTC
Changed
-9.14%
Net income
Changed
-67.74%
Free cash flow
Changed
-44.51%
Cash
What changed
↓Net income declined 9.1%, showing weaker profitability.
↓Free cash flow declined 67.7%, indicating pressure on cash generation.
↓Cash and short-term investments declined 44.5%.
Based on newly processed financial statements and comparable prior-period data.This is informational analysis, not investment advice.
Financial data as of: Jun 30, 2026, 12:00 AM UTCLast earnings update: Sep 4, 2026, 11:12 AM UTCLast profile update: Sep 4, 2026, 12:16 PM UTC
Company Snapshot
Key valuation, quality, financial strength, momentum and analyst data.
Price$3.88
Change-1.02%
Market Cap$4.05M
52W Range3.29 - 13.20
Beta0.67
Gross Margin0.00%
Oper. Margin0.00%
Profit Margin0.00%
Debt/Eq0.00
Current Ratio6.55
Quick Ratio6.55
Volume12.06K
Price$3.88
Change-1.02%
Market Cap$4.05M
52W Range3.29 - 13.20
Beta0.67
Gross Margin0.00%
Oper. Margin0.00%
Profit Margin0.00%
Debt/Eq0.00
Current Ratio6.55
Quick Ratio6.55
Volume12.06K
Avg Volume75.78K
EPS Surprise-0.29
Investment DNA
How strong this company looks for long-term investors
47
out of 100
Business Quality
Margins, moat, returns
22/100
Financial Strength
Debt, cash, stability
70/100
Growth Potential
Revenue and expansion
50/100
Price Attractiveness
Cheap or expensive today
95/100
Why this score▼
Manageable debt level · 0Healthy liquidity · 6.55Weak profitability
Analyst view
No analyst data available now.
🧾
No insider activity
No recent insider transactions available.